Identification

Name
Fencamfamine
Accession Number
DB01463
Type
Small Molecule
Groups
Approved, Illicit, Withdrawn
Description

Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases. [Wikipedia]

Structure
Thumb
Synonyms
  • Fencamfamin
  • Fencamfamine
  • Fencamfaminum
  • Fencanfamina
Product Ingredients
IngredientUNIICASInChI Key
Fencamfamine hydrochloride0M1J60BWEX2240-14-4CVFSMSTXULJISA-UHFFFAOYSA-N
International/Other Brands
Glucoenergan / Reactivan
Categories
UNII
NME1I5IGBK
CAS number
1209-98-9
Weight
Average: 215.3339
Monoisotopic: 215.167399677
Chemical Formula
C15H21N
InChI Key
IKFBPFGUINLYQI-UHFFFAOYSA-N
InChI
InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3
IUPAC Name
N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
SMILES
CCNC1C2CCC(C2)C1C1=CC=CC=C1

Pharmacology

Indication

For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.

Structured Indications
Not Available
Pharmacodynamics

Fencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being. It is a central nervous system stimulant, which increases locomotor activity.

Mechanism of action

Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The drug seems to inhibit the dopamine transporter (DAT) that removes dopamine from the synapses. This inhibition of DAT blocks the reuptake of dopamine and norepinephrine into the presynaptic neuron, increasing the amount of dopamine in the synapse. It also stimulates the release of dopamine and norepinephrine into the synapse. Finally, it increases the magnitude of dopamine release after a stimulus, increasing the salience of stimulus. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer. Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.

TargetActionsOrganism
ASodium-dependent dopamine transporter
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Overdosage is characterised by nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage the above symptoms may also be associated with dyspnoea, tachycardia, disorientation and convulsions.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineFencamfamine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFencamfamine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFencamfamine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fencamfamine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fencamfamine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fencamfamine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fencamfamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amperozide.Experimental
AmphetamineFencamfamine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fencamfamine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Azaperone.Investigational, Vet Approved
AzelastineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fencamfamine.Approved
BenzphetamineFencamfamine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fencamfamine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fencamfamine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fencamfamine.Approved, Investigational
BuprenorphineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fencamfamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fencamfamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fencamfamine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fencamfamine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fencamfamine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fencamfamine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fencamfamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fencamfamine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fencamfamine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorphenamine.Approved
ChlorphentermineFencamfamine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fencamfamine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fencamfamine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fencamfamine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Fencamfamine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fencamfamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fencamfamine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fencamfamine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fencamfamine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fencamfamine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fencamfamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fencamfamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fencamfamine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fencamfamine.Approved, Vet Approved
DextroamphetamineFencamfamine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fencamfamine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fencamfamine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fencamfamine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fencamfamine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Diethyl ether.Experimental
DiethylpropionFencamfamine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fencamfamine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fencamfamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fencamfamine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fencamfamine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fencamfamine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fencamfamine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fencamfamine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fencamfamine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fencamfamine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fencamfamine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fencamfamine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fencamfamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fencamfamine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fencamfamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fencamfamine.Approved
EthanolFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fencamfamine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Felbamate.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fencamfamine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fencamfamine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fencamfamine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fencamfamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fencamfamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fencamfamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fencamfamine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fencamfamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fencamfamine.Approved, Illicit, Investigational
GepefrineFencamfamine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fencamfamine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fencamfamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fencamfamine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fencamfamine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fencamfamine.Approved
HydrocodoneFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fencamfamine.Approved, Illicit
HydroxyamphetamineFencamfamine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Indiplon.Investigational
Iofetamine I-123Fencamfamine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fencamfamine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fencamfamine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fencamfamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fencamfamine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fencamfamine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fencamfamine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fencamfamine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fencamfamine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fencamfamine.Approved, Investigational
LisdexamfetamineFencamfamine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Fencamfamine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fencamfamine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fencamfamine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fencamfamine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fencamfamine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fencamfamine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Melperone.Approved, Investigational
MephedroneFencamfamine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFencamfamine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fencamfamine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Meptazinol.Experimental
MequitazineFencamfamine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fencamfamine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fencamfamine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fencamfamine.Approved, Illicit
MethamphetamineFencamfamine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fencamfamine.Approved
MethotrimeprazineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fencamfamine.Approved, Investigational, Vet Approved
MethoxyphenamineFencamfamine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fencamfamine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fencamfamine.Approved, Investigational
MetyrosineFencamfamine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine.Approved, Illicit
MidomafetamineFencamfamine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Fencamfamine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Investigational
MirtazapineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAFencamfamine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fencamfamine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fencamfamine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fencamfamine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fencamfamine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fencamfamine.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fencamfamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fencamfamine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fencamfamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fencamfamine.Approved
OpiumThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Opium.Approved, Illicit
OrphenadrineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fencamfamine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fencamfamine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fencamfamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fencamfamine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fencamfamine.Approved
ParaldehydeFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fencamfamine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fencamfamine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fencamfamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fencamfamine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fencamfamine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fencamfamine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenoxyethanol.Approved
PhentermineFencamfamine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fencamfamine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pomalidomide.Approved
PramipexoleFencamfamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fencamfamine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fencamfamine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fencamfamine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fencamfamine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fencamfamine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fencamfamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fencamfamine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fencamfamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Fencamfamine is combined with PSD502.Investigational
PseudoephedrineFencamfamine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fencamfamine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fencamfamine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fencamfamine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fencamfamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fencamfamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fencamfamine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fencamfamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ritanserin.Investigational
RitobegronFencamfamine may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fencamfamine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Romifidine.Vet Approved
RopiniroleFencamfamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fencamfamine.Approved
RotigotineFencamfamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fencamfamine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fencamfamine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fencamfamine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Fencamfamine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fencamfamine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fencamfamine.Approved, Investigational
SuvorexantFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fencamfamine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fencamfamine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fencamfamine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetrodotoxin.Investigational
ThalidomideFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fencamfamine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fencamfamine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fencamfamine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fencamfamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fencamfamine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fencamfamine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fencamfamine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fencamfamine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fencamfamine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fencamfamine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fencamfamine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Fencamfamine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fencamfamine.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fencamfamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fencamfamine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fencamfamine.Approved, Investigational
ZolpidemFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fencamfamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fencamfamine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. DeLucia R, Planeta CS: Fencamfamine. Gen Pharmacol. 1990;21(2):161-3. [PubMed:1970543]
  2. Link [Link]
External Links
Human Metabolome Database
HMDB15508
PubChem Compound
14584
PubChem Substance
46508161
ChemSpider
13922
ChEBI
134895
ChEMBL
CHEMBL7010
Therapeutic Targets Database
DAP001007
PharmGKB
PA164747055
Wikipedia
Fencamfamine
ATC Codes
N06BA06 — Fencamfamin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.20SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00295 mg/mLALOGPS
logP3.46ALOGPS
logP3.21ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)10.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity67.64 m3·mol-1ChemAxon
Polarizability26.13 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9756
Caco-2 permeable+0.6244
P-glycoprotein substrateNon-substrate0.648
P-glycoprotein inhibitor IInhibitor0.5239
P-glycoprotein inhibitor IIInhibitor0.6499
Renal organic cation transporterNon-inhibitor0.5876
CYP450 2C9 substrateNon-substrate0.7441
CYP450 2D6 substrateNon-substrate0.6052
CYP450 3A4 substrateNon-substrate0.6348
CYP450 1A2 substrateInhibitor0.871
CYP450 2C9 inhibitorNon-inhibitor0.6742
CYP450 2D6 inhibitorInhibitor0.7272
CYP450 2C19 inhibitorInhibitor0.645
CYP450 3A4 inhibitorNon-inhibitor0.7812
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8237
Ames testNon AMES toxic0.7967
CarcinogenicityNon-carcinogens0.7716
BiodegradationNot ready biodegradable0.6553
Rat acute toxicity3.3827 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7712
hERG inhibition (predictor II)Inhibitor0.5827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Bicyclic monoterpenoids
Alternative Parents
Aromatic monoterpenoids / Aralkylamines / Benzene and substituted derivatives / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Bicyclic monoterpenoid / Aromatic monoterpenoid / Aralkylamine / Benzenoid / Monocyclic benzene moiety / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Seyfried CA: Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31. [PubMed:6136281]
  2. Li SM, Campbell BL, Katz JL: Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J Pharmacol Exp Ther. 2006 Jun;317(3):1088-96. Epub 2006 Feb 14. [PubMed:16478825]

Drug created on July 31, 2007 07:09 / Updated on December 01, 2017 17:16